Study of Eribulin in Children With Cancer to Determine Safety

Stopped early · Phase 1

Conditions studied: Pediatric Cancer, Solid Tumors, Lymphoma

In brief

This is a study for children with cancer with no curative treatment options. The investigators will be giving eribulin, a new chemotherapy agent, for the first time to children. This study is designed to determine a safe dose the investigators can give to children in larger studies. The investigators will be monitoring the children on this study for the safety of the treatment and levels of eribulin in the blood after treatment. The investigators will also study the effect of the agent on the cancer.

Key facts

Study ID

NCT02082626

Run by

University of Oklahoma

People needed

3

Starts

2014-02-01

Expected to finish

2018-06-01

Last updated by the study team

2020-03-10

Who can join

Age: any, up to 20. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: ≤ 21 years of age at the time of study enrollment
• Diagnosis: refractory or recurrent solid tumors, including lymphomas, except those with CNS tumors or known CNS metastases
• Disease Status: measurable or evaluable disease
• Adequate organ function as defined in protocol

You may not qualify if…

• Pregnant or breastfeeding

Where it is running

• Jimmy Everest Center for Cancer and Blood Disorders in Children — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.